+72%

est. 2Y upside i

HealthcareSeries C

Stage: growth. Country: United States of America

Rank

#684

Sector

Clinical AI / Healthcare Technology

Est. Liquidity

~3Y

Data Quality

Data: Medium

Nabla offers a high-risk, high-reward equity opportunity.

Last updated: July 19, 2026

Bull (10%)+150%

Strong IPO window and category leadership sustain a 9x revenue multiple. Revenue reaches $54M, driving exit value to $486M, netting 150% upside after 20pp dilution.

Base (50%)+90%

Multiple converges to peer average of 7x on $54M revenue, yielding $378M exit. After 20pp dilution, upside is 90%.

Bear (40%)+30%

Multiple compresses to 5x due to incumbent pressure and slower growth. Exit at $270M, still above $120M preferred, yielding 30% upside after dilution.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

67%

Total funding of $120M is 66.7% of current valuation, significantly diluting common stock value.

Dilution Risk

moderate

Likely need to raise capital within 24 months given cash burn; assumed 20% dilution.

Secondary Liquidity

none

No secondary market activity reported.

Customer Success — 4 roles

Engineering — 4 roles

Product — 3 roles

Sales — 2 roles

Finance — 1 role

Marketing — 1 role

View all 15 open roles at Nabla →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Nabla's data — designed to show you've done your homework.

  • 1

    “How does Nabla plan to differentiate and win against Microsoft/Nuance's deep EHR integrations?”

  • 2

    “What is the average contract value and customer acquisition cost?”

  • 3

    “Given the $120M preference overhang, what is the common stock's current implied value per share?”

Community

Valuation Sentiment

Our model estimates +72% upside. What do you think?

Anonymous. Do not share material non-public information.


Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.